Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Disease Attributes

All Drugs and Chemicals

Vaccines

BCG Vaccine

Monatide (IMS 3015)

DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.

MPHOSPH1 and DEPDC1

Tomoaki Fujioka, M.D. & Ph.D.

The purpose of this study is to evaluate the clinical efficacy for the prevention of the recurrence for bladder cancer after TUR-Bt

DEP domain containing 1(DEPDC1) and M phase phosphoprotein 1(MPHOSPH1) have been identified using genome-wide expression profile analysis by the use of cDNA microarray in our previous studies. The investigators have determined the HLA-A\*2402 restricted epitope peptides derived from DEPDC1, DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278. These epitopes showed strong IFN-g production when stimulated with the appropriate targets expressed the appropriate protein and HLA-A\*2402. Furthermore, when vaccinated these peptides, specific CTLs were determined after the vaccination. Therefore we focused on the prevention of the recurrence of the bladder cancer after surgery using these peptides.

Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer

Phase II Study of Bladder Cancer Using Novel Tumor Antigens for Prevention of the Recurrence for Bladder Cancer After TUR-Bt

Human Genome Center, Institute of Medical Science, University of Tokyo

Iwate Medical University

Department of Urology

DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.

The purpose of this study is to evaluate the safety and clinical efficacy of novel vaccination for advanced bladder cancer.

DEP domain containing 1(DEPDC1) and M phase phosphoprotein 1(MPHOSPH1) have been identified using genome-wide expression profile analysis by the use of cDNA microarray in our previous studies. We have determined the HLA-A\*2402 restricted epitope peptides derived from DEPDC1, DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278. These epitopes showed strong IFN-g production when stimulated with the appropriate targets expressed the appropriate protein and HLA-A\*2402. Furthermore, when vaccinated these peptides, specific CTLs were determined after the vaccination. Therefore we focused on the safety and efficacy of novel vaccination for the advanced bladder cancer patients who already showed resistance to standard chemotherapies or radiotherapy.

Novel Peptide Vaccination for Patients With Advanced Bladder Cancer

Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	NCT00633204	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	NCT00633204	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	NCT00633204	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	NCT00633204	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer	NCT00635336	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer	NCT00635336	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University

Spots Global Cancer Trial Database for mphosph1 and depdc1